Keywords: Russia, NSCLC, Lung cancer, Market forecasts, Decision Resources, Kinase inhibitors

Russia’s NSCLC market set to grow to $163 million in 2015

Article | 15 December 2011

The Russian market for non-small-cell lung cancer (NSCLC) therapies will grow 3% annually from 2010 to reach a value of $163 million in 2015, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in